New Results

Upregulation of Somatostatin Receptor Type 2 in a Receptor-Deficient In Vivo Pancreatic Neuroendocrine Tumor Model Improves Tumor Response to Targeted 177Lu-DOTATATE

Rupali Sharma, Bhargav Earla, Kwamena Baidoo, Martha A. Zeiger, James P. Madigan, Freddy E. Escorcia, Samira M. Sadowski
doi: https://doi.org/10.1101/2022.04.25.489401

Article usage

Article usage: April 2022 to December 2023

AbstractFullPdf
Apr 20226351166
May 20222251530
Jun 2022361014
Jul 202243923
Aug 202253612
Sep 202246813
Oct 20226159
Nov 202261816
Dec 202282912
Jan 20232177
Feb 2023231519
Mar 202344816
Apr 2023381017
May 202327511
Jun 2023501510
Jul 20233769
Aug 2023181112
Sep 202333813
Oct 202318812
Nov 202330139
Dec 2023421
Back to top
Posted April 26, 2022.
Download PDF

Supplementary Material

Email
Upregulation of Somatostatin Receptor Type 2 in a Receptor-Deficient In Vivo Pancreatic Neuroendocrine Tumor Model Improves Tumor Response to Targeted 177Lu-DOTATATE
Rupali Sharma, Bhargav Earla, Kwamena Baidoo, Martha A. Zeiger, James P. Madigan, Freddy E. Escorcia, Samira M. Sadowski
bioRxiv 2022.04.25.489401; doi: https://doi.org/10.1101/2022.04.25.489401
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area